Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Abstract 4509: Genetically encoded chimeric polypeptide nanoparticles for paclitaxel delivery to triple negative breast cancer.

Publication ,  Conference
Bhattacharyya, J; McDaniel, J; Chilkoti, A
Published in: Cancer Research
April 15, 2013

Triple negative breast cancer (TNBC) represents an important clinical challenge, because TNBC, like other breast cancer subtypes is highly metastatic, but TNBC displays a shorter median time to relapse and death. Chemotherapy remains the mainstay of treatment of TNBC, as it gives a markedly higher response rate than endocrine therapy or other available targeted agents. Current treatment strategies for TNBC include treatment with anthracyclines, taxanes, and platinates. Like other drugs, paclitaxel shows a lack of selectivity towards tumor cells, sub-optimal pharmacokinetics and bio-distribution, leading to limited efficacy and significant systemic toxicity. Although AbraxaneTM (albumin bound paclitaxel) an improved formulation of paclitaxel compared to the original chremophor formulation has been used to treat TNBC, it also suffers from systemic toxicity such as sensory neuropathy, neutropenia, nausea, and anemia.In an effort to overcome the limited efficacy and systemic toxicity of current paclitaxel formulations, we have designed a novel polypeptide drug delivery system where paclitaxel is covalently attached to a genetically engineered chimeric polypeptide (CP) through a pH sensitive linker such that covalent conjugation of multiple copies of Paclitaxel at one end of the CP spontaneously triggers the self-assembly of the drug-CP conjugate into sub 100 nm size nanoparticles that are ideal for targeting solid tumors through the enhanced permeability and retention (EPR) effect.We found that in a human triple negative breast cancer cell (MDA-MB-231), the CP-paclitaxel conjugate showed substantial cytotoxicity that was similar to free drug. CP-Paclitaxel nanoparticle treated mice with orthotopic MDA-MB-231 tumors showed significantly greater tumor regression as well as enhanced overall survival compared to free drug. These results are promising because they demonstrate the potential of rationally engineered nanoparticle drug carriers to greatly improve the efficacy of currently approved cytotoxic agents for the treatment of solid tumors. In future work, we will evaluate the efficacy of CP-Paclitaxel nanoparticles combined with a tyrosine kinase inhibitor that mimics current combination chemotherapy.Citation Format: Jayanta Bhattacharyya, Jonathan McDaniel, Ashutosh Chilkoti. Genetically encoded chimeric polypeptide nanoparticles for paclitaxel delivery to triple negative breast cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4509. doi:10.1158/1538-7445.AM2013-4509

Duke Scholars

Published In

Cancer Research

DOI

EISSN

1538-7445

ISSN

0008-5472

Publication Date

April 15, 2013

Volume

73

Issue

8_Supplement

Start / End Page

4509 / 4509

Publisher

American Association for Cancer Research (AACR)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bhattacharyya, J., McDaniel, J., & Chilkoti, A. (2013). Abstract 4509: Genetically encoded chimeric polypeptide nanoparticles for paclitaxel delivery to triple negative breast cancer. In Cancer Research (Vol. 73, pp. 4509–4509). American Association for Cancer Research (AACR). https://doi.org/10.1158/1538-7445.am2013-4509
Bhattacharyya, Jayanta, Jonathan McDaniel, and Ashutosh Chilkoti. “Abstract 4509: Genetically encoded chimeric polypeptide nanoparticles for paclitaxel delivery to triple negative breast cancer.” In Cancer Research, 73:4509–4509. American Association for Cancer Research (AACR), 2013. https://doi.org/10.1158/1538-7445.am2013-4509.
Bhattacharyya J, McDaniel J, Chilkoti A. Abstract 4509: Genetically encoded chimeric polypeptide nanoparticles for paclitaxel delivery to triple negative breast cancer. In: Cancer Research. American Association for Cancer Research (AACR); 2013. p. 4509–4509.
Bhattacharyya, Jayanta, et al. “Abstract 4509: Genetically encoded chimeric polypeptide nanoparticles for paclitaxel delivery to triple negative breast cancer.Cancer Research, vol. 73, no. 8_Supplement, American Association for Cancer Research (AACR), 2013, pp. 4509–4509. Crossref, doi:10.1158/1538-7445.am2013-4509.
Bhattacharyya J, McDaniel J, Chilkoti A. Abstract 4509: Genetically encoded chimeric polypeptide nanoparticles for paclitaxel delivery to triple negative breast cancer. Cancer Research. American Association for Cancer Research (AACR); 2013. p. 4509–4509.

Published In

Cancer Research

DOI

EISSN

1538-7445

ISSN

0008-5472

Publication Date

April 15, 2013

Volume

73

Issue

8_Supplement

Start / End Page

4509 / 4509

Publisher

American Association for Cancer Research (AACR)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis